Skip to content

Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations
Endometrial Carcinoma Fireside Chat *Post-Test*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.Diarrhea, nausea, and vomiting are common gastrointestinal toxicities associated with the use of pembrolizumab and lenvatinib combination therapy. Which other toxicity may occur if these gastrointestinal toxicities are not managed effectively?(Required.)
3.During treatment with pembrolizumab and lenvatinib, a patient develops grade 3 diarrhea. Lenvatinib is held and loperamide is prescribed, but grade 3 diarrhea persists. Which of the following would be an appropriate next step for this patient?(Required.)
4.A patient has been receiving a combination of pembrolizumab and lenvatinib for the past 12 months. At their most recent follow-up appointments they have presented with persistently high levels of thyroid stimulating hormone. Lenvatinib was withheld, but TSH levels remain high. Which drug might you suspect is the most likely underlying cause of this toxicity?(Required.)
5.During treatment with pembrolizumab and lenvatinib, a patient develops grade 3 hypertension. What is the most effective management strategy for this patient?(Required.)
EVALUATION FORM
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
EXPRESS awareness of AEs associated with anti-angiogenic therapy and how they differ from immune-mediated AEs
DIFFERENTIATE etiology and presentation of overlapping toxicities with AA/IO combination therapy
SELECT optimal strategies to prevent and manage common AEs experienced by patients treated with AA/IO combination therapy
7.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources and/or handouts provided to me at the educational activity are useful to my practice
8.Overall, was this activity fair, balanced and free from commercial bias?
9.If no, please explain:
10.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
11.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
12.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
13.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
14.I certify that I have participated in the continuing education activity entitled, "Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations | Endometrial Carcinoma Fireside Chat" and claim 0.5 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice